MULTICENTER RANDOMIZED, OPEN-LABEL PHASE II/III STUDY, TO COMPARE EFFICACY OF NBTXR3 IMPLANTED AS INTRATUMOR INJECTION AND ACTIVATED BY RADIOTHERAPY, VERSUS RADIOTHERAPY ALONE IN PATIENTS WITH LOCALLY ADVANCED SOFT TISSUE SARCOMA (EXTREMITY AND TRUNK WALL)

Trial Profile

MULTICENTER RANDOMIZED, OPEN-LABEL PHASE II/III STUDY, TO COMPARE EFFICACY OF NBTXR3 IMPLANTED AS INTRATUMOR INJECTION AND ACTIVATED BY RADIOTHERAPY, VERSUS RADIOTHERAPY ALONE IN PATIENTS WITH LOCALLY ADVANCED SOFT TISSUE SARCOMA (EXTREMITY AND TRUNK WALL)

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 15 Jun 2017

At a glance

  • Drugs NBTXR 3 (Primary)
  • Indications Soft tissue sarcoma
  • Focus Registrational; Therapeutic Use
  • Acronyms Act.in.sarc
  • Sponsors Nanobiotix; PharmaEngine
  • Most Recent Events

    • 15 Jun 2017 According to a Nanobiotix media release, the data from this study was presented at Immunotherapy workshop - Incorporating Radiation Oncology into Immunotherapy.
    • 18 May 2017 Results published in the Nanobiotix media release.
    • 24 Apr 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top